Grantham Mayo Van Otterloo & Co. LLC Has $3.09 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Grantham Mayo Van Otterloo & Co. LLC grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 735.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,115 shares of the specialty pharmaceutical company’s stock after purchasing an additional 22,108 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Jazz Pharmaceuticals were worth $3,093,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. Centre Asset Management LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $9,335,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at $464,000. Franklin Resources Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Jazz Pharmaceuticals by 13.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock worth $4,420,000 after acquiring an additional 4,332 shares during the last quarter. Finally, Sanctuary Advisors LLC increased its holdings in Jazz Pharmaceuticals by 502.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company’s stock worth $1,310,000 after purchasing an additional 9,804 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $106.93 on Tuesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a fifty day moving average of $131.92 and a 200-day moving average of $123.06. The firm has a market capitalization of $6.49 billion, a P/E ratio of 15.06, a P/E/G ratio of 1.04 and a beta of 0.42.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on JAZZ shares. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Morgan Stanley reissued an “overweight” rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price target for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. HC Wainwright boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Finally, Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,736 shares of company stock valued at $4,023,305. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.